Lookup NU author(s): Dr Therese Hannon
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© 2017 The Author(s). Background: Severe, early-onset fetal growth restriction due to placental insufficiency is associated with a high risk of perinatal mortality and morbidity with long-lasting sequelae. Placental insufficiency is the result of abnormal formation and function of the placenta with inadequate remodelling of the maternal spiral arteries. There is currently no effective therapy available. Some evidence suggests sildenafil citrate may improve uteroplacental blood flow, fetal growth, and meaningful infant outcomes. The objective of the Sildenafil TheRapy In Dismal prognosis Early onset fetal growth Restriction (STRIDER) collaboration is to evaluate the effectiveness of sildenafil versus placebo in achieving healthy perinatal survival through the conduct of randomised clinical trials and systematic review including individual patient data meta-analysis. Methods: Five national/bi-national multicentre randomised placebo-controlled trials have been launched. Women with a singleton pregnancy between 18 and 30 weeks with severe fetal growth restriction of likely placental origin, and where the likelihood of perinatal death/severe morbidity is estimated to be significant are included. Participants will receive either sildenafil 25 mg or matching placebo tablets orally three times daily from recruitment to 32 weeks gestation. Discussion: The STRIDER trials were conceived and designed through international collaboration. Although the individual trials have different primary outcomes for reasons of sample size and feasibility, all trials will collect a standard set of outcomes including survival without severe neonatal morbidity at time of hospital discharge. This is a summary of all the STRIDER trial protocols and provides an example of a prospectively planned international clinical research collaboration. All five individual trials will contribute to a pre-planned systematic review of the topic including individual patient data meta-analysis.
Author(s): Pels A, Kenny LC, Alfirevic Z, Baker PN, von Dadelszen P, Gluud C, Kariya CT, Mol BW, Papageorghiou A, van Wassenaer-Leemhuis AG, Ganzevoort W, Groom KM, McCowan LM, Stone PR, Lee A, Mackay L, Oyston C, Gardener G, Khashan A, Eustace J, Dempsey E, Jackson R, Dickinson J, Gill A, Muller P, Sekar R, Reid RA, Unterschneider J, Welsh A, Marlow J, Hyett J, Walker S, Morris J, Watson D, McKinlay C, Harris S, von Dadelszen P, Lim KI, Lalji S, Magee LA, Lim KI, Magee LA, Lalji S, Kariya CT, Lee T, Li J, Hutfield A, Ansermino M, Robinson W, Singer J, Synnes AR, Burrows J, Audibert F, Bujold E, Piedboeuf B, Piedboeuf B, Davidge ST, Seaward GR, Dwinnell S, Gagnon R, Gaudet L, Young C, Murphy D, Daly S, McAuliffe F, Malone F, Breathnach F, O'Donoghue K, Ganzevoort JW, Pels A, Al-Nasiry S, de Boer MA, de Groot CJM, Sueters M, Derks JB, van Drongelen J, Duvekot HJ, Elvan-Taspinar A, van Eyck J, van Laar J, Morssink LP, Alfirevic Z, Price L, Astor A, Hardman L, Sharp A, Turner M, Cameron A, Draper E, Clarke P, Mckelvey A, Papageorghiou A, Alfirevic Z, Masson G, Aquilin J, Johnstone E, Bugg G, Howe D, Patni S, Mousa H, Russell H, Hannon T, Kilby M, David A, Cohen K, Impey L, Stock S, Poon L, Pasupath D, Khalil A, Baker PN
Publication type: Article
Publication status: Published
Journal: BMC Pregnancy and Childbirth
Online publication date: 28/12/2017
Acceptance date: 23/11/2017
ISSN (electronic): 1471-2393
Publisher: BioMed Central Ltd.
Altmetrics provided by Altmetric